within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M01C_SpecificAntirheumaticAgents.M01CC02_Bucillamine;

model Bucillamine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.7,
    Cl = 6.666666666666666e-07,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.0004,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0006666666666666666,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Bucillamine</td></tr><tr><td>ATC code:</td><td>M01CC02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.4</td><td>L</td></tr>
    <tr><td>clearance:</td><td>2.4</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Bucillamine is a disease-modifying antirheumatic drug (DMARD) structurally related to D-penicillamine. It is primarily used in Japan and South Korea for the treatment of rheumatoid arthritis and is not approved in most other countries. Bucillamine exerts anti-inflammatory and immunomodulatory effects, serving as a thiol donor with antioxidant properties.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult population, oral administration, based on analogies with D-penicillamine and available clinical summaries in Japanese prescribing information sources. No direct publication of detailed PK parameter values was found in the literature.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.M.M01CC02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Bucillamine;
